January 07, 2019 Japanese biopharma rules mid-cap returns Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
October 10, 2018 Mid-cap investors see Eastern promise in the third quarter Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap players.
